Accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection
Congratulations to Onyx Pharmaceuticals on the accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection, a proteasome inhibitor for the treatment of patients with multiple myeloma. Read the official press release.
For some analysts take on business ramifications, see:
http://www.onclive.com/web-exclusives/FDA-Approves-Carfilzomib-for-Relapsed-Multiple-Myeloma,
http://www.fiercepharma.com/
Disclaimer: CDD’s Barry Bunin was on one of the early patents for carfilzomib: Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C. Compounds for Enzyme Inhibition. Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc). Proteolix was acquired by Onyx Pharmaceuticals:
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Other posts you might be interested in
View All Posts
CDD Blog
8 min
July 22, 2024
Drug Discovery Industry Roundup with Barry Bunin — July, 22 2024
Read More
CDD Blog
34 min
July 1, 2024
Critical Data Considerations for All Lifecycle Stages of a Biotech Startup
Read More
CDD Vault Snack
3 min
June 27, 2024
Vault Snack #24 - New Interface, Features & Infrastructure for the CDD Vault ELN
Read More